Lawsuit Overview - A securities class action lawsuit has been filed against Cassava Sciences Inc (NASDAQ: SAVA) in the United States District Court for the Western District of Texas [1] - The lawsuit is on behalf of investors who purchased or acquired Cassava securities between February 7, 2024, and November 24, 2024 [1] - The lead plaintiff deadline is February 10, 2025 [1] Allegations Against Cassava Sciences - Defendants allegedly made materially false and/or misleading statements during the Class Period [3] - Defendants failed to disclose material adverse facts about the company's business, operations, and prospects [3] - Specifically, Cassava's drug simufilam was not capable of abating the progression of Alzheimer's Disease, even in mild to moderate cases [3] - As a result, Defendants' statements about the company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis [3] Lead Plaintiff Process - Cassava investors may seek to be appointed as a lead plaintiff representative of the class no later than February 10, 2025 [4] - The lead plaintiff is usually the investor or small group of investors with the largest financial interest who are also adequate and typical of the proposed class [4] - The lead plaintiff selects counsel to represent the lead plaintiff and the class [4] - Investors' ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff [4] Law Firm Information - Kessler Topaz Meltzer & Check LLP is prosecuting the class action [5] - The firm has recovered billions of dollars for victims of fraud and other corporate misconduct [5] - The firm's goal is to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries [5]

RADNOR, Pa., Jan. 03, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. (“Cassava”) (NASDAQ: SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the “Class Period”). The lead plaintiff deadline is February 10, ...

NEW YORK, Jan. 3, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cassava Sciences, Inc. investors who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/psl ...

RADNOR, Pa., Dec. 30, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the "Class Period"). The lead plaintiff deadline is February 10, 2025 ...

NEW ORLEANS, Dec. 27, 2024 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM: SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the "Class Period"). This action is pending in the United States District Court for the Western District of Texas.Get HelpCassava inves ...

RADNOR, Pa., Dec. 27, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. (“Cassava”) (NASDAQ: SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the “Class Period”). The lead plaintiff deadline is February 10, ...

Core Viewpoint - Levi & Korsinsky, LLP has initiated a class action securities lawsuit on behalf of investors in Cassava Sciences, Inc. due to alleged securities fraud impacting the company's stock performance [2][3]. Group 1: Lawsuit Details - The lawsuit targets losses incurred by Cassava Sciences, Inc. investors from February 7, 2024, to November 24, 2024, related to alleged securities fraud [3]. - The complaint alleges that defendants misled investors regarding the efficacy of Cassava's drug candidate, simufilam, particularly in treating Alzheimer's Disease [4]. - Following the release of disappointing Phase 3 study results for simufilam on November 25, 2024, the stock price plummeted from $26.48 to $4.30, marking a decline of approximately 83.76% in one day [4]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until February 10, 2025, to request appointment as lead plaintiff in the lawsuit [5]. - Participation in the lawsuit does not require investors to incur any out-of-pocket costs or fees [5].

NEW YORK, Dec. 26, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form-2/?id=118159&from=4CLASS PERIOD: Februar ...

NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the “Class Period”), of the important February 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...

NEW YORK, Dec. 23, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form-2/?id=117775&from=4 CLASS PERIOD: Februa ...